Health
FDA declines to approve Summit's lung cancer drug ivonescimab over lack of survival benefit
The U.S. Food and Drug Administration has declined to approve Summit Therapeutics' lung cancer drug ivonescimab, a decision linked to the drug not showing a survival benefit, according to STAT News and Reuters.